11
Introduction 28
The transcription factor p53 serves as a central hub in the transcriptional response to DNA 29 damage(1). p53 directly binds a consensus response element (RE) sequence within gene 30 promoters and enhancers to activate a cell and organism-protective gene regulatory network (2). 31
This transcriptional response involves upregulation of numerous genes involved in cell cycle 32 arrest, apoptosis, DNA repair, and metabolic pathways (3, 4). As loss of p53 activity is highly potential parallel DNA damage pathways. 48
49
The dynamics of p53 protein stabilization and subsequent cellular-level phenotypes 50 depend on the method used to activate p53, with significant differences observed within different 51 DNA damage paradigms or nutlin 3A (11, 12) . Exposure to gamma irradiation lead to oscillating 52 p53 protein levels over a 24-hour period whereas UV treatment produces sustained p53 levels 53 with an overall higher amplitude. In contrast, single doses of nutlin 3A lead to rapid p53 54 stabilization that is later reversed due to both nutlin 3A degradation and increased p53-55 dependent expression of MDM2. These p53 dynamics appear to control the ultimate outcomes of 56 p53 activation such as the decision to commit to senescence or apoptosis, for example (11, 12) . 57
Although the dynamics of p53 protein levels are directly influenced by the method of p53 58 stabilization, whether this leads to differential p53:DNA binding or gene activation is less clear 59 (13-16). 60 61
The first wave of genome-scale p53 ChIP-seq experiments suggested high spatial variability 62 of p53 binding in response to various p53 activating conditions, even within the same cell type 63 (14, 15, (17) (18) (19) . Reanalysis of these datasets and multiple other p53 ChIP-seq datasets from a 64 variety of transformed cell types and p53 stabilization methods suggested p53 DNA binding is 65 much less variable (13, 20) . Approximately 1,000 p53 binding sites display high concordance 66 across multiple labs, cell types, and experimental methods when consistent data processing 67 methods are used (13). Conversely, two recent pre-prints demonstrate widespread cell type-68 specific p53 binding events that are driven by differences in chromatin accessibility (21, 22) . A 69 recent multi-omics approach suggests that high affinity p53 binding sites are shared across cell 70 types, whereas the observed cell type-specific binding events were lower affinity sites (23). 71 72 We therefore sought to better understand functional differences between genotoxic and 73 non-genotoxic stabilization of p53 and the resulting transcriptomes. Here, we find that 74 stabilization of p53 by genotoxic (etoposide) and non-genotoxic (nutlin 3A) methods yield nearly 75 identical DNA binding within highly similar local chromatin environments. Direct p53 binding 76 sites are characterized by high levels of H4K16ac, while indirect ChIP-seq-derived p53 binding 77 events are found within highly accessible, promoter regions. Genotoxic activation of p53 using 78 etoposide leads to significantly more activated gene targets than using nutlin 3A, with the majority 79 of these genes classified as inflammatory response genes. Expression of these etoposide-activated 80 genes is abrogated by treatment with NF-kB pathway inhibitors, suggesting a DNA damage-81 dependent, but p53-independent, mechanism of action. These data provide increased evidence 82 that p53 engagement with the genome and transcriptional targets are cell type-intrinsic and that 83 careful analysis of crosstalk between DNA damage signaling pathways is prudent. 84 85
Results 86
Comparison of p53 interaction with the genome after genotoxic and non-genotoxic 87 activation 88 89 We used low-passage (PD 25-30) primary human fibroblasts (IMR90) cultured under 90 normoxic conditions (3% O2) to assess whether p53-mediated gene expression and genome 91 binding dynamics vary based on the method of p53 stabilization and activation. Of note, the 92 majority of published datasets regarding p53 activity have been performed using 20% O2. 93
Etoposide is a commonly used chemotherapeutic that inhibits topoisomerase II, leading to a 94 failure to resolve dsDNA breaks and activation of p53 through an ATM-mediated signaling cascade 95 (24, 25). Phosphorylation of p53 at serine 15 disrupts the interaction with the E3 ligase MDM2 96 and results in stabilization of the p53 protein (26). The small molecule Nutlin-3A is an inhibitor of 97 the p53:MDM2 interaction, and leads to stabilization and activation of p53a in the absence of DNA 98 damage or p53-S15ph ( Fig.1A , (7) Treatment with either 100uM Etoposide or 5uM nutlin 3A lead 99 to similar p53 and p21 (a canonical target of p53) protein accumulation 6 hours post-treatment 100 compared to a DMSO vehicle control ( Fig. 1A) , suggesting approximately equivalent effects on p53 101 stabilization and activity. Etoposide treatment led to an increase in phosphorylation of serine 15 102 ( Fig. 1A) , which is downstream of DNA damage-dependent kinases and is required for endogenous 103 stabilization of p53 after DNA damage (1). 104
105
We then used chromatin immunoprecipitation coupled to highly parallel sequencing (ChIP-106 seq) to determine the genomewide binding sites of p53 after 6 hours of treatment with 100uM 107 etoposide and compared this treatment to previously published datasets for DMSO and nutlin 108 (27) . Importantly, all p53 ChIP-seq experiments were performed using identical conditions (27). 109
The resulting genome alignment and peak calling data for all experiments can be found in 110 Supplemental Table 1 . Treatment with either nutlin or etoposide dramatically increased the 111 number of observed input-normalized p53 peaks compared to DMSO vehicle controls ( Fig. 1B) , 112 with more statistically enriched peaks (FDR > 0.01) observed after treatment with nutlin 3A than 113 with etoposide. The large majority of p53 binding events in both conditions contain a full 114 canonical p53 response element motif (86% and 82% for nutlin 3A and etoposide, respectively) as 115 determined by p53scan (19), and de novo motif finding using HOMER (28) yielded highly similar 116 DNA elements underlying nutlin 3A and etoposide induced p53 binding sites (Supplemental Table  117 2). 118
119
In order to identify putative functional differences between two p53 activating conditions, 120 we analyzed whether nutlin and etoposide-induced p53 binding events occurred within similar 121 genomic loci. We parsed peaks by the presence of a canonical p53 response element motif (motif 122 positive) and those lacking such a motif (motif negative) using p53scan (19) and then performed 123 peak overlap analysis using bedTools (29). Over 90% of etoposide p53 motif+ peaks intersect with 124 nutlin 3A motif+ peaks (Fig. 1C , left), while we observe nearly 1,500 nutlin 3A-specific p53 binding events are observed independent of p53 activation method when considering enrichment instead 140 of strict peak calling methods. This is in contrast to previous reports using peak calling 141 methodologies (14, 15), but similar to meta-analyses of those (and other) data showing high 142 similarity across p53 conditions when considering ChIP enrichment (13). Our data demonstrate 143 that p53 engagement with the genome is highly similar between non-genotoxic (nutlin 3A) and 144 genotoxic (etoposide) stabilization methods. Further, these results suggest that p53 ChIP-seq 145 peaks lacking canonical p53 motifs are quite variable and do not correlate between stabilization 146 conditions, suggesting they represent experimental or technical artifacts commonly observed in We next asked whether there were any distinguishing features of p53 ChIP-seq peaks 178 containing or lacking canonical p53 motifs (2). Motif+ peaks displayed higher input-substracted 179 p53 ChIP enrichment in both nutlin and etoposide conditions compared to p53 motif-peaks ( Fig.  180 2D, p53). This is consistent with previous reports that the p53 motif is the primary determinant 181 for binding affinity (2, 18, 27). Motif-peaks show significantly higher enrichment of RNA 182 polymerase II, H3K4me3, H3K27ac, and ATAC-seq tags than motif+ peaks ( Fig. 2D ). As motif-183 peaks are also more closely localized to TSS ( Fig binding events occur more proximally to p53-dependent genes than p53-independent genes (Fig. 270 3D and (23)), we analyzed the distance of etoposide and nutlin 3A-specific genes to p53 binding 271 sites. The median distance between p53 binding events and common p53 target genes is 24.8 kb 272 ( Fig. 5C ). This distance increases to over 170 kb and 140 kb for etoposide or nutlin 3A-specific 273 genes, respectively, and is, significantly further than the median distance for bona fide p53 targets 274 pathway. We therefore tested the possibility that etoposide-specific activated genes are NF-kB-280 dependent and p53-independent. The p65 subunit of the NF-kB complex is repressed by the 281 activity of IkB and is derepressed by phosphorylation by IkK (50-52) . Bay 11-7082 is a small 282 molecule inhibitor of the Ik kinase family and suppresses NF-kB pathway signaling by maintaining 283 the inactive state of p65 (53). We performed RT-qPCR for three canonical p53 targets and three 284 etoposide-specific inflammatory targets after treatment with IkK inhibitors and activation of p53 285 by nutlin or etoposide (Figs. 6A-B) . The p53 canonical targets CDKN1A, BBC3, and MDM2 are 286 activated in response to both nutlin 3A and etoposide treatment and are unaffected by co-287 treatment with Bay 11-1043 ( Fig. 6A , ratio paired t test). In contrast, IL8, IL1A, and IL1B are all 288 activated specifically after etoposide treatment (Fig. 6B , * p<0.01, ** p<0.001, ratio paired t test), 289 similar to our initial RNA-seq observations (Fig. 3A) . Further, co-treatment with Bay 11-7082 290 abrogates etoposide-induced expression of these genes (Fig. 6B, * p<0 .01, ** p<0.001, ratio paired 291 t test) suggesting these genes are downstream of DNA damage-induced NF-kB signaling. 292
293
We extended this analysis by surveying the polyA+ transcriptome after treatment with p53 294 activators and NF-kB signaling pathway inhibition with Bay-11-7082. We identified four strong 295 gene clusters in response to co-treatment with p53 activators and Bay 11-7082 treatment using k-296 means clustering (Fig. 6C) . Three groups contained genes that are specifically upregulated by 297 etoposide treatment and are strongly repressed when co-treated with Bay 11-7082 ( Fig. 6C,  298 Sensitive). Another cluster contained genes whose etoposide-induced expression was insensitive 299 to treatment with Bay 11-7082 ( Fig. 6C, Insensitive) . Broadly, treatment with Bay-11-7082 300 reduces expression of etoposide-specific targets after nutlin 3A treatment (Fig. 6D , nutlin vs. 301 nutlin/bay, p=0.0033, Mann Whitney U), suggesting some of these genes are basally regulated by 302 NF-kB signaling. Bay-11-7082 treatment strongly reduces expression of the etoposide-specific 303 gene set relative to no treatment ( Fig. 6D . p<2e -16 , Mann Whitney U). Gene Ontology analysis of the 304 Bay-sensitive gene network confirmed these genes are associated with NF-kB pathway and 305 inflammatory signaling, consistent with our hypothesis that these genes are likely NF-kB targets. 306
Genes found in the Bay 11-7082-insensitive cluster were less enriched in total GO terms, but are 307 related to apoptosis and immune signaling. These genes are therefore putative DNA damage-308 dependent, but likely NF-kB independent, target genes. 309 310 Discussion 311 312 Using comparative genomic approaches, we have demonstrated a highly conserved 313 transcriptional and chromatin response to both genotoxic and non-genotoxic p53 stabilization 314 methods. Binding of p53 to chromatin is highly similar across experimental conditions, with the 315 majority of differences attributed to peak calling approaches. This observation is remarkably 316 similar to a recent report of highly conserved p53 binding across cell types and experimental p53 317 activation methods using a meta-analysis approach (13). One key aspect of this work is the use of 318 a uniform methodology for genome alignment, peak calling, and statistical thresholding across 319 laboratory and experimental conditions. We used a similar approach by first using macs2 to call 320 significant peaks and then creating a combined peak list between experiments (54). Then, we 321 counted tag enrichment within the combined peak regions for both nutlin 3A and etoposide 322 conditions, which yielded strikingly similar enrichment profiles (Figs. 1D-E). Condition-specific 323 peaks (called by macs2) had higher tag counts within the peak region than did the other condition 324 ( Fig. 1E ), but the overall profile between nutlin 3A and etoposide-induced p53 binding were well 325 correlated (Fig. 1D ). Taken together, these data provide additional evidence that p53 engagement 326 with the genome is highly consistent within the same cell type when activated by disparate 327 methods. It is important to note that our analysis was only performed after p53 activation with the 328 (55, 56), especially within the N-terminus (57). These modifications include multiple 339 phosphorylation events in the first transactivation domain of p53, which may help to block the 340 interaction between p53 and MDM2, leading to p53 stabilization. The N-terminus of p53 contains 341 two independent trans-activation domains (TADs), both of which can be extensively modified 342 (57-59). Our data suggest that p53 DNA binding and p53-dependent gene activation are 343 consistent between p53 stabilization methods even though our data suggest that at least serine 15 344 is differentially phosphorylated between nutlin 3A and etoposide-treated conditions (Fig. 1A) . ChIP-seq datasets (13) suggests high similarity of p53 binding across cell types. One caveat is that 388 the majority of the analyzed data were from either mesenchymal fibroblast cell lines or 389 transformed cell lines. A conserved core group of p53 binding sites across three cancer cell lines 390 was also recently observed (23), but of note, each cell type had a unique spectrum of binding 391 events. Two recent works suggest that cell type-dependent chromatin accessibility leads to varied 392 p53 binding, which could explain differential p53-induced inflammatory target genes (21, 22 ). An 393 analysis of 12 transformed human cell lines demonstrates specific p53 binding to cell type-specific 394 accessible chromatin(22), including specific p53 binding to the IL1A locus in the metastatic 395 melanoma LOXIMVI cell line. In primary mammary epithelial cells, p53 binds to two separate 396 active enhancers between IL1A and IL1B and leads to a p53-dependent activation of those genes 397 (21). The chromatin modification and accessibility-based markers suggest these enhancers are 398 inactive in skin or lung fibroblast and that p53 is unable to bind to these regions (21, 27) . Our data 399 demonstrate that these genes are not activated by p53 in lung fibroblasts in response to nutlin 3A 400 or etoposide treatment (21, 27). Cell type-specific chromatin accessibility and enhancer activity 401 provides a powerful and intriguing mechanism for differential regulation of p53 target genes. 402
403
In summary, our work provides a comprehensive comparison of p53 binding, chromatin 404 state, and transcriptional activity in primary lung fibroblasts exposed to either genotoxic or non-405 genotoxic activators of p53. We propose that p53 activity and chromatin/RNA polymerase II 406 dynamics are highly correlated within the same cell type regardless of the method of p53 407 stabilization, and that crosstalk between other DNA damage-activated transcription factors likely 408 contribute to any observed transcriptional differences or cellular phenotypes. Illumina NextSeq 500 (NF-kB inhibitor experiments). Resulting raw data were aligned to the hg19 447 assembly using TopHat2/Bowtie2 (68). Differentially expressed genes were those with at least 2-448 fold difference between the treated condition and the comparable DMSO-treated condition. 449 450 ATAC-seq: Assay for transposase-accessible chromatin (ATAC-seq) was performed as described 451 (34). Briefly, proliferating IMR90 cells were treated with DMSO, nutlin 3A, or etoposide as 452 described above and harvested by centrifugation. 50,000 cells were resuspended in ATAC lysis 453 buffer and incubated on ice for 5 minutes before pelleting at 500 x G for 5 minutes at 4˚C. Lysis 454 buffer was then removed and nuclei were immediately resuspended in 50uL of transposase 455 reaction mix (1X TD Buffer, 2.5uL of Nextera Transposase). The transposase reaction was 456 incubated at 37˚C for 30 minutes before the reaction was stopped by purification with Qiagen 457 Supplemental Table 3 . C. Distance of nutlin-694 specific, etoposide-specific, or commonly upregulated genes to the nearest p53 motif-containing 695 p53 peak. 696 
